Aclaris Therapeutics Inc. (ACRS)
NASDAQ: ACRS
· Real-Time Price · USD
2.10
0.03 (1.45%)
At close: Sep 05, 2025, 3:59 PM
2.10
0.00%
After-hours: Sep 05, 2025, 05:24 PM EDT
Aclaris Therapeutics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract research Revenue | 442K | 445K | 1.24M | 645K | 625K | 657K | 1.27M | 705K | 875K | 889K | 866K | 1.09M | 1.22M | 1.22M | 1.27M |
| Contract research Revenue Growth | -0.67% | -64.08% | +92.09% | +3.20% | -4.87% | -48.31% | +80.28% | -19.43% | -1.57% | +2.66% | -20.55% | -10.51% | -0.25% | -4.16% | n/a |
| License and Service Revenue | 1.33M | 1.01M | 10.74M | 3.7M | 2.14M | 1.74M | 25.58M | 8.58M | 994K | 1.64M | 6.72M | 17.9M | n/a | n/a | n/a |
| License and Service Revenue Growth | +32.18% | -90.59% | +190.11% | +72.86% | +22.98% | -93.19% | +198.25% | +762.88% | -39.35% | -75.62% | -62.44% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 5.39M | 6.14M | 4.95M | 5.65M | 4.65M | 4.34M | 8.21M | 7.09M | 8.32M | 8.79M | 7.15M | 5.81M | 6.08M | 6.1M | 6.94M | 5.98M | 5.87M | 4.83M | 4.9M | 3.86M | 5.57M | 6.2M | 5.81M | 6.29M | 15.17M | 18.02M | 19.66M | 17.95M | 18.99M | 17.49M | 11.99M | 8.12M | 6.33M | 5.16M | 4.68M | 3.65M | 3.15M | 3.6M | 2.4M | 1.23M | 803K | 892K |
| Selling, General, and Administrative Revenue Growth | -12.27% | +23.92% | -12.37% | +21.52% | +7.09% | -47.11% | +15.84% | -14.74% | -5.38% | +23.01% | +22.93% | -4.31% | -0.39% | -12.16% | +16.12% | +1.86% | +21.61% | -1.45% | +26.92% | -30.74% | -10.13% | +6.73% | -7.59% | -58.55% | -15.84% | -8.34% | +9.51% | -5.45% | +8.55% | +45.87% | +47.63% | +28.33% | +22.72% | +10.12% | +28.33% | +15.76% | -12.51% | +50.17% | +94.81% | +53.42% | -9.98% | n/a |
| Research and Development Revenue | 11.45M | 11.58M | 9.03M | 5.96M | 8.76M | 9.85M | 26.65M | 23.88M | 25.27M | 22.59M | 21.07M | 23.66M | 18.78M | 14.31M | 14.1M | 13.98M | 7.9M | 7.84M | 8.96M | 6.87M | 6.47M | 9.44M | 11.54M | 16.18M | 17.62M | 19.92M | 19.54M | 15.93M | 13.98M | 13.61M | 13.19M | 10.86M | 7.96M | 7.77M | 6.94M | 7.16M | 9.84M | 9.54M | 2.4M | 9.41M | 1.79M | 1.74M |
| Research and Development Revenue Growth | -1.17% | +28.34% | +51.54% | -32.00% | -11.03% | -63.05% | +11.60% | -5.54% | +11.90% | +7.19% | -10.92% | +25.97% | +31.27% | +1.45% | +0.90% | +76.98% | +0.75% | -12.48% | +30.44% | +6.19% | -31.53% | -18.16% | -28.69% | -8.17% | -11.53% | +1.96% | +22.64% | +13.92% | +2.78% | +3.16% | +21.40% | +36.40% | +2.48% | +11.94% | -3.06% | -27.19% | +3.16% | +296.96% | -74.47% | +424.71% | +3.22% | n/a |